

Date: 1st June, 2023

To,
The Deputy Gen. Manager,
Metropolitan Stock Exchange of India Ltd.
Vibgyor Towers, 4th Floor, Plot No. C-62, G-Block,
Opp. Trident, Bandra-Kurla Complex,
Bandra (E), Mumbai-400 098

Dear Sir / Madam,

Sub: Outcome of Board Meeting of Jagadishwar Pharmaceutical Works Limited held on 1st June, 2023.

Ref: Regulation 33 (3) of SEBI (Listing Obligation and Disclosures Requirements) Regulations 2015

With reference to the above captioned subject, outcome of the meeting of the Board of Directors of Jagadishwar Pharmaceutical Works Limited which was held today at 03.00 p.m. and concluded at 03.30 p.m. is as follows:

Approved Audited Standalone Financial Results of the Company for the quarter and year ended on March 31, 2023.

Find enclosed herewith a copy of Audited Standalone Financial Results along with Auditors Report pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

The Report of Auditors is with unmodified opinion with respect to the Audited Standalone Financial Results of the Company for the year ended March 31, 2023.

You are requested to take note of the same.

Thanking You,

Yours Faithfully,

For Jagadishwar Pharmaceutical Works Limited

Swapan Sarkar
Director
DIN: 05149442

Encl: As above

Jagadishwar Pharmaceutical Works Limited
(CIN : L24232AS1987PLC002803)

Regd. Office: 205, Haribol Roy Market, A.T.Road, 2nd Floor, Near Saraf Building, Guwahati - 781 001

Corp. Office : 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email ID: jpw ltd@yahoo.com, **Website:** jagadishwarpharma.com, **Tel:** +91 9163513015

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2023


(Rs. In lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2023 (Audited)	31-12-2022 (Unaudited)	31-03-2022 (Audited)	31-03-2023 (Audited)	31-03-2022 (Audited)
I	Income From Operations	-	-	-	-	1.85
II	Other Income	10.76	11.26	11.36	44.14	50.61
III	Total Income from operations (I + II)	10.76	11.26	11.36	44.14	52.46
IV	Expenses					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Purchase of stock-in-trade	2.77	-	-	2.77	3.04
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2.77)	-	-	(2.77)	(1.19)
	(d) Employee benefits expense	5.49	5.55	4.94	25.11	20.19
	(e) Depreciation and amortisation expense	-	-	-	-	-
	(f) Finance Cost	-	-	-	-	-
	(g) Other expenses	2.00	2.07	2.15	10.50	10.81
	Total Expenses	7.49	7.62	7.08	35.60	32.85
V	Profit (Loss) before exceptional Items and extraordinary items and tax (III-IV)	3.27	3.64	4.28	8.54	19.61
VI	Exceptional Items	-	-	-	-	6.84
VII	Profit from ordinary activities before finance costs and Exceptional Items (V-VI)	3.27	3.64	4.28	8.54	12.76
VIII	Extra Ordinary Items	-	-	-	-	-
IX	Net Profit/(Loss) before tax (VII-VIII)	3.27	3.64	4.28	8.54	12.76
X	Tax Expense :					
	(1) Current Tax	2.22	-	3.38	2.22	3.38
	(2) Deferred Tax	-	-	-	-	-
	Total Tax Expenses	2.22	-	3.38	2.22	3.38
XI	Net profit /(Loss) for the period from continuing operations (IX-X)	1.05	3.64	0.90	6.32	9.38
XII	Profit /(Loss) for the period from discontinuing operations	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-
XIV	Profit /(Loss) for the period from discontinuing operations (after tax)	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	1.05	3.64	0.90	6.32	9.38
XVI	Other Comprehensive Income	13.41	-	(6.37)	13.41	(6.37)
XVII	Total Comprehensive Income	14.46	3.64	(5.47)	19.73	3.01
XVIII	Paid up equity share capital (Face Value of Rs.10/- per Share)	2,970.02	2,970.02	2,970.02	2,970.02	2,970.02
XIX	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	115.67	112.66
XX	Earnings Per Share (EPS)					
	(a) Basic	0.00	0.01	0.00	0.02	0.03
	(b) Diluted	0.00	0.01	0.00	0.02	0.03

Notes:

- The above audited standalone financial results for the quarter and year ended 31 March 2023 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 1st June, 2023.
- Figures for the quarter ended 31 March, 2023 and corresponding quarter ended in the previous year as reported in these standalone financial results are the balancing figures in respect of the full financial year and the published year-to-date figures up to the end of third quarter of the relevant financial year. Also the figures upto the end of third quarter had only been reviewed and not subjected to audit.
- The standalone financial results of the Company for the quarter and year ended 31st March, 2023 have been audited by the Statutory Auditors.
- The Statutory Auditors of the Company have conducted audit of these financial results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and have issued Audit Report with unmodified opinion
- Previous period/Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited


Swapan Sarkar
 Director

Place: Kolkata

Dated: 1st June, 2023

(DIN : 05149442)

Jagadishwar Pharmaceutical Works Limited
(CIN : L24232AS1987PLC002803)

AUDITED STATEMENTS OF ASSETS AND LIABILITIES		(Rs. In Lacs)	
Sr. No.	Particulars	As at 31-03-2023	As at 31-03-2022
		Audited	Audited
A)	Assets		
1)	Non Current Assets		
	a) Fixed Assets	-	-
	b) Goodwill on consolidation	-	-
	c) Non-current investments	1,309.36	1,295.94
	d) Long term loans and advances	3.52	4.15
	e) Other Non current assets	-	-
	Sub Total-Non Current Assets	1,312.87	1,300.09
2)	Current Assets		
	a) Current Investments	-	-
	b) Inventories	433.06	430.29
	c) Trade receivables	-	-
	d) Cash and Cash equivalents	12.59	64.71
	e) Short term loans and advances	511.43	476.98
	f) Other current assets	835.57	813.72
	Sub Total-Total Current Assets	1,792.65	1,785.70
	Total Assets	3,105.53	3,085.79
B)	Equity and Liabilities		
1)	Shareholders Fund		
	a) Share Capital	2,970.02	2,970.02
	b) Reserves and Surplus	135.41	115.67
	Sub Total- Shareholders Fund	3,105.43	3,085.69
2)	Non-Current Liabilities		
	a) Long term borrowings	-	-
	b) Other Long term Liabilities	-	-
	c) Long term provisions	-	-
	Sub Total- Non Current Liabilities	-	-
3)	Current Liabilities		
	a) Short term borrowings	-	-
	b) Trade payables	-	-
	c) Other current Liabilities	-	-
	d) Other short term provisions	0.10	0.10
	Sub Total-Current Liabilities	0.10	0.10
	Total -Equity and Liabilities	3,105.53	3,085.79

For Jagadishwar Pharmaceutical Works Limited

Swapan Sarkar

Swapan Sarkar

Director

(DIN : 05149442)

Place: Kolkata

Dated: 1st June, 2023



Jagadishwar Pharmaceutical Works Limited

CIN: L24232AS1987PLC002803

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2023

Rs. In Lakh

PARTICULARS		As at 31 March, 2023 Amount (Rs.)	As at 31 March, 2022 Amount (Rs.)
A.	<u>Cash Flow from Operating Activities</u>		
	Net Profit/(Loss) before tax	8.54	12.76
	Add : Depreciation	-	-
	Add: Interest Expenses	-	-
	Add: Loss on sale of Fixed Asset	-	-
	Less :Interest Income	(44.14)	(50.61)
	Operating Profit before Working Capital Changes	(35.60)	(37.86)
	Adjustment for :		
	Non Current Financial Assets	-	-
	Other Non Current Assets	-	-
	Inventories	(2.77)	(1.19)
	Trade Receivable	-	-
	Other Current Assets	(21.85)	(190.95)
	Loans and Advances	(34.45)	240.85
	Trade payable and other Liabilities	-	-
	Other Financial Liabilities	-	-
	Other Current Liabilities	0.00	-
	Net Cash inflow from/(outflow) from operating activities	(94.67)	10.85
B.	<u>Cash Flow from Investing Activities</u>		
	Sale Proceeds from Fixed Assets	-	-
	Interest Received	44.14	50.61
	Fixed Assets Purchase	-	-
	Income Tax Paid	(1.59)	(5.06)
	Net Cash inflow from/(outflow) from Investing Activities	42.55	45.55
C.	<u>Cash Flow from Financing Activities</u>		
	Proceeds from Borrowing	-	-
	Interest paid	-	-
	Dividend Paid	-	-
	Net Cash inflow from/(outflow) from Financing Activities	-	-
	Net Increase /(decrease) in cash and Cash Equivalents	(52.12)	56.41
	Opening Cash and Cash Equivalents		
	Cash in Hand	7.96	6.97
	Bank balances	56.75	1.33
	Total	64.71	8.30
	Closing Cash and Cash Equivalents		
	Cash in Hand	9.45	7.96
	Bank balances	3.14	56.75
	Total	12.59	64.71

For Jagadishwar Pharmaceutical Works Limited

Swapan Sarkar
Director
DIN : 05149442

Place: Kolkata

Dated: 1st June, 2023



Auditors Report on Quarterly Financial Result and Year to Date Result of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligation and Discourse requirements) Regulations, 2015

To,
The Board of Directors
Jagadishwar Pharmaceutical Works Limited


We have audited the quarterly financial result of **Jagadishwar Pharmaceutical Works Limited** for the quarter ended **March 31, 2023** and the year to date result for the period April 01, 2022 to March 31, 2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. These quarterly financial result as well as the year to date financial result have been prepared on the basis of interim financial Statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements which have been prepared in accordance with the recognition and measurement principle laid down in Accounting standard 25 of interim Financial Reporting (IND AS), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principle generally accepted in India.

We conducted our audit in accordance with the auditing standard generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial result are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial result. An audit also includes assessing the accounting principle used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial result as well as the year to date result

- (i) Have been presented in accordance with requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 in this regard; and
- (ii) Gave a true and fair view of the financial information including other comprehensive income and other financial information for the quarter ended March 31, 2023 as well as the year to date result for the period from April 01, 2022 to March 31, 2023.

For **Rajesh U Shah & Associates**
Chartered Accountants


Rajesh Shah
Proprietor



Membership Number: 056550
Firm Regn. No.: 327799E
UDIN: 23056550062FQY2373

Place: Kolkata
Date: 01-06-2023

Date: 01/06/2023

To,
The Deputy Gen. Manager,
Metropolitan Stock Exchange of India Ltd.
Vibgyor Towers, 4th Floor, Plot No. C-62, G-Block,
Opp. Trident, Bandra-Kurla Complex,
Bandra (E),
Mumbai-400 098

Subject: Declaration confirming issuance of Audited Reports with 'Unmodified Opinion' on Standalone Financial Statement of Jagadishwar Pharmaceutical Works Limited the Company for the financial year ended 31st March, 2023.

Pursuance to regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements Regulation, 2015 (LODR). I, Swapan Sarkar, Director of the Company do hereby declare and confirm that Statutory Auditors of the Company i.e. M/s. Rajesh U Shah & Associates, Chartered Accountants have issued their Audit Report with Unmodified Opinion on the Standalone Financial Result Company for the financial year ended 31st March, 2023.

Kindly take the same on your record.

For Jagadishwar Pharmaceutical Works Limited


Swapan Sarkar

Swapan Sarkar
Director

DIN: 05149442